Seek Returns

ARGX vs. VTRS: argenx vs. Viatris Stock Comparison

How do argenx (ARGX) and Viatris (VTRS) stack up? This page sets them side by side across company profile, performance and risk, profitability, growth, financial strength, dividends, and valuation, with selected fundamentals also measured against each stock's industry-group peers.

Company Profile

argenx (ARGX) and Viatris (VTRS) both fall under the Pharmaceuticals, Biotechnology & Life Sciences industry group, but ARGX is classified in Biotechnology while VTRS is classified in Pharmaceuticals.

Viatris (VTRS) trades as ordinary local shares, while argenx (ARGX) trades as an ADR — compare with FX exposure, depositary-program fees, and dividend-withholding-tax differences in mind.

Company profile comparison for argenx (ARGX) and Viatris (VTRS)
Profile ItemARGXVTRS
Nameargenx SE American Depositary ReceiptViatris Inc.
Country/RegionNetherlandsUnited States
GICS SectorHealth CareHealth Care
GICS Industry GroupPharmaceuticals, Biotechnology & Life SciencesPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryBiotechnologyPharmaceuticals
GICS Sub-IndustryBiotechnologyPharmaceuticals
Market Capitalization58.31 billion USD22.83 billion USD
CurrencyUSDUSD
ExchangeNasdaqNasdaq
Listing DateMay 18, 2017March 17, 1980
Security TypeADRCommon Stock

Price Performance

Cumulative Growth

ARGX
VTRS
GSPC
Loading price history…
argenx (ARGX) vs. Viatris (VTRS), with S&P 500 (GSPC) for reference: Growth of a $10,000 investment over the past five years. Adjusted for dividends and splits.

Trailing Returns

Loading price history…
Trailing total returns for argenx (ARGX) and Viatris (VTRS). Returns over one year are annualized.

Calendar-Year Returns

Loading price history…
Calendar-year total returns for argenx (ARGX) and Viatris (VTRS). Each bar is that year's total return, measured year-end to year-end.

Performance Metrics

Price performance metrics for argenx (ARGX) and Viatris (VTRS)
MetricARGXVTRS
Total Return (1Y)11.91%108.98%
Total Return (3Y, Annualized)25.68%36.75%
Total Return (5Y, Annualized)24.22%11.59%

Risk Profile

Drawdown History

ARGX
VTRS
GSPC
Loading price history…
argenx (ARGX) vs. Viatris (VTRS), with S&P 500 (GSPC) for reference: Drawdown from the running peak over the past five years. Each line shows the decline from its prior peak; 0% marks a new high.

Return Distribution

Loading price history…
Distribution of monthly total returns for argenx (ARGX) and Viatris (VTRS). Each bar is the share of months whose return fell in that 5% bucket.

Risk Metrics

Risk profile metrics for argenx (ARGX) and Viatris (VTRS)
MetricARGXVTRS
Volatility (1Y, Annualized)37.87%32.53%
Beta (5Y)0.450.86
Max Drawdown (5Y)-38.20%-45.69%
Avg. Volume (3M)359.84K8.87M

Risk-Adjusted Performance

Risk-Return Positioning

Loading chart…
ARGX and VTRS are plotted by 1-year volatility (risk) and 1-year return. The dashed Capital Allocation Line runs from the risk-free rate through the shared industry median.

Risk-Adjusted Metrics

Risk-adjusted metrics for argenx (ARGX) and Viatris (VTRS)
MetricARGXVTRS
Sharpe Ratio (1Y)0.203.22
Sortino Ratio (1Y)0.315.63

Profitability

ROE (TTM)

argenx (ARGX) has no ROE value reported for this period; Viatris (VTRS) reports a negative figure of -4.21%, which needs context because negative ROE can reflect losses or negative shareholders’ equity.

ARGX

Pharmaceuticals, Biotechnology & Life Sciences industry group

--

Max
109.18%
Q3
6.23%
Median
-26.66%
Q1
-64.05%
Min
-167.77%
ARGX
--

VTRS

Pharmaceuticals, Biotechnology & Life Sciences industry group

-4.21%

Max
109.18%
Q3
6.23%
VTRS
-4.21%
Median
-26.66%
Q1
-64.05%
Min
-167.77%
Loading chart…
argenx (ARGX) vs. Viatris (VTRS): ARGX does not report ROE, so it has no value marker; VTRS is benchmarked against the Pharmaceuticals, Biotechnology & Life Sciences industry group.

Net Margin (TTM)

Viatris (VTRS) reports a negative net margin of -4.13%, usually indicating a net loss over the period. Meanwhile argenx (ARGX) reports 31.73%, ranking against industry peers normally.

ARGX

Pharmaceuticals, Biotechnology & Life Sciences industry group

31.73%

ARGX
31.73%
Max
18.05%
Q3
4.78%
Median
0.00%
Q1
-4.14%
Min
-17.05%

VTRS

Pharmaceuticals, Biotechnology & Life Sciences industry group

-4.13%

Max
18.05%
Q3
4.78%
Median
0.00%
VTRS
-4.13%
Q1
-4.14%
Min
-17.05%
Loading chart…
argenx (ARGX) vs. Viatris (VTRS): A comparison of their net margin against the Pharmaceuticals, Biotechnology & Life Sciences industry group benchmark.

Operating Margin (TTM)

argenx (ARGX) at 36.27% operates in the top operating margin quartile, ahead of Viatris (VTRS) at 13.85%, which runs around its industry’s norm.

ARGX

Pharmaceuticals, Biotechnology & Life Sciences industry group

36.27%

Max
83.12%
ARGX
36.27%
Q3
14.77%
Median
0.00%
Q1
-78.82%
Min
-207.40%

VTRS

Pharmaceuticals, Biotechnology & Life Sciences industry group

13.85%

Max
83.12%
Q3
14.77%
VTRS
13.85%
Median
0.00%
Q1
-78.82%
Min
-207.40%
Loading chart…
argenx (ARGX) vs. Viatris (VTRS): A comparison of their operating margin against the Pharmaceuticals, Biotechnology & Life Sciences industry group benchmark.

Profitability Metrics

Profitability metrics for argenx (ARGX) and Viatris (VTRS)
MetricARGXVTRS
ROE (TTM)---4.21%
ROA (TTM)--2.91%
Net Margin (TTM)31.73%-4.13%
Operating Margin (TTM)36.27%13.85%
Gross Margin (TTM)59.84%41.13%

Growth

Revenue Growth

argenx (ARGX) at 89.64% sits in the top revenue growth quartile, while Viatris (VTRS) at -2.98% is in the bottom quartile, showing a clear gap in revenue momentum.

Loading chart…
argenx (ARGX) vs. Viatris (VTRS): A comparison of their Revenue Growth across different time periods.

EPS Growth

Only one side can be read here: argenx (ARGX) reports EPS growth of 53.13%, ranked against its industry; Viatris (VTRS) has no EPS growth figure this period.

Loading chart…
argenx (ARGX) vs. Viatris (VTRS): A comparison of their EPS Growth across different time periods.

Growth Metrics

Growth metrics for argenx (ARGX) and Viatris (VTRS)
MetricARGXVTRS
Revenue Growth (YoY)89.64%-2.98%
Revenue Growth (3Y CAGR)116.25%-4.20%
EPS Growth (YoY)53.13%--
EPS Growth (3Y CAGR)----

Financial Strength

Current Ratio (MRQ)

Short-term liquidity can only be read on one side of this pairing: Viatris (VTRS) shows current ratio of 1.55 against its industry benchmark, while argenx (ARGX) has no reading this period.

ARGX

Pharmaceuticals, Biotechnology & Life Sciences industry group

--

Max
25.13
Q3
12.13
Median
5.52
Q1
2.47
Min
0.10
ARGX
--

VTRS

Pharmaceuticals, Biotechnology & Life Sciences industry group

1.55

Max
25.13
Q3
12.13
Median
5.52
Q1
2.47
VTRS
1.55
Min
0.10
Loading chart…
argenx (ARGX) vs. Viatris (VTRS): ARGX does not report current ratio, so it has no value marker; VTRS is benchmarked against the Pharmaceuticals, Biotechnology & Life Sciences industry group.

Debt / Equity (MRQ)

argenx (ARGX) at 0.01 keeps leverage in the lower quartile, while Viatris (VTRS) at 0.99 sits in the higher-leverage quartile.

ARGX

Pharmaceuticals, Biotechnology & Life Sciences industry group

0.01

Max
1.42
Q3
0.65
Median
0.15
Q1
0.02
ARGX
0.01
Min
0.00

VTRS

Pharmaceuticals, Biotechnology & Life Sciences industry group

0.99

Max
1.42
VTRS
0.99
Q3
0.65
Median
0.15
Q1
0.02
Min
0.00
Loading chart…
argenx (ARGX) vs. Viatris (VTRS): A comparison of their debt-to-equity ratio against the Pharmaceuticals, Biotechnology & Life Sciences industry group benchmark.

Financial Strength Metrics

Financial strength metrics for argenx (ARGX) and Viatris (VTRS)
MetricARGXVTRS
Current Ratio (MRQ)--1.55
Debt / Equity (MRQ)0.010.99
Net Debt / EBITDA-2.702.64

Dividends

Dividend Yield (TTM)

argenx (ARGX) pays no dividend (yield 0.00%) — it may be reinvesting, using buybacks, or simply not returning cash through dividends. Meanwhile Viatris (VTRS) reports a yield of 2.53%, ranking against industry peers normally.

ARGX

Pharmaceuticals, Biotechnology & Life Sciences industry group

0.00%

ARGX
0.00%
Max
0.00%
Q3
0.00%
Median
0.00%
Q1
0.00%
Min
0.00%

VTRS

Pharmaceuticals, Biotechnology & Life Sciences industry group

2.53%

VTRS
2.53%
Max
0.00%
Q3
0.00%
Median
0.00%
Q1
0.00%
Min
0.00%
Loading chart…
argenx (ARGX) vs. Viatris (VTRS): A comparison of their dividend yield against the Pharmaceuticals, Biotechnology & Life Sciences industry group benchmark.

Dividend Payout Ratio (TTM)

Viatris (VTRS) reports payout ratio above 100% at 960.00%, meaning dividends exceeded current-period earnings; argenx (ARGX) pays no dividend (payout 0.00%).

ARGX

Pharmaceuticals, Biotechnology & Life Sciences industry group

0.00%

ARGX
0.00%
Max
0.00%
Q3
0.00%
Median
0.00%
Q1
0.00%
Min
0.00%

VTRS

Pharmaceuticals, Biotechnology & Life Sciences industry group

960.00%

VTRS
960.00%
Max
0.00%
Q3
0.00%
Median
0.00%
Q1
0.00%
Min
0.00%
Loading chart…
argenx (ARGX) vs. Viatris (VTRS): A comparison of their payout ratio against the Pharmaceuticals, Biotechnology & Life Sciences industry group benchmark.

Dividend Metrics

Dividend metrics for argenx (ARGX) and Viatris (VTRS)
MetricARGXVTRS
Dividend Yield (TTM)0.00%2.53%
Dividend Payout Ratio (TTM)0.00%960.00%

Valuation

P/E Ratio (TTM)

An earnings multiple is available for just one side: argenx (ARGX) trades at 32.12 times trailing earnings, ranked against its peers, while Viatris (VTRS) has no P/E ratio this period.

ARGX

Pharmaceuticals, Biotechnology & Life Sciences industry group

32.12

Max
85.34
Q3
43.46
ARGX
32.12
Median
26.69
Q1
13.30
Min
0.07

VTRS

Pharmaceuticals, Biotechnology & Life Sciences industry group

--

Max
85.34
Q3
43.46
Median
26.69
Q1
13.30
Min
0.07
VTRS
--
Loading chart…
argenx (ARGX) vs. Viatris (VTRS): VTRS does not report P/E ratio, so it has no value marker; ARGX is benchmarked against the Pharmaceuticals, Biotechnology & Life Sciences industry group.

P/S Ratio (TTM)

Viatris (VTRS) at 1.55 sits in the cheaper P/S ratio quartile while argenx (ARGX) at 9.86 prices around its industry’s middle — VTRS costs less per dollar of sales, though read it alongside growth and margins.

ARGX

Pharmaceuticals, Biotechnology & Life Sciences industry group

9.86

Max
58.18
Q3
25.77
ARGX
9.86
Median
7.30
Q1
3.01
Min
0.01

VTRS

Pharmaceuticals, Biotechnology & Life Sciences industry group

1.55

Max
58.18
Q3
25.77
Median
7.30
Q1
3.01
VTRS
1.55
Min
0.01
Loading chart…
argenx (ARGX) vs. Viatris (VTRS): A comparison of their P/S ratio against the Pharmaceuticals, Biotechnology & Life Sciences industry group benchmark.

P/B Ratio (MRQ)

Viatris (VTRS) at 1.67 sits in the lower P/B ratio quartile relative to book while argenx (ARGX) at 172.23 prices above its industry range — a wide valuation gap against assets.

ARGX

Pharmaceuticals, Biotechnology & Life Sciences industry group

172.23

ARGX
172.23
Max
13.53
Q3
6.54
Median
3.25
Q1
1.69
Min
-5.59

VTRS

Pharmaceuticals, Biotechnology & Life Sciences industry group

1.67

Max
13.53
Q3
6.54
Median
3.25
Q1
1.69
VTRS
1.67
Min
-5.59
Loading chart…
argenx (ARGX) vs. Viatris (VTRS): A comparison of their P/B ratio against the Pharmaceuticals, Biotechnology & Life Sciences industry group benchmark.

Valuation Metrics

Valuation metrics for argenx (ARGX) and Viatris (VTRS)
MetricARGXVTRS
P/E Ratio (TTM)32.12--
P/S Ratio (TTM)9.861.55
P/B Ratio (MRQ)172.231.67
Free Cash Flow Yield (TTM)--13.84%